RxSight offers a revolutionary adjustable IOL technology with superior outcomes and reduced side effects compared to traditional IOLs. The company's "razor-and-blade" business model, with the LAL and ...

Please provide your email address to receive an email when new articles are posted on . TAMPA, Fla. — The Light Adjustable Lens optimizes postoperative results after cataract surgery, a speaker said ...

CEO Dr. Ron Kurtz highlighted that Q1 2025 revenue was impacted by a weakened premium intraocular lens (IOL) market, disruptions from sequential product launches by competitors, and macroeconomic ...

Sold 27,579 Light Adjustable Lenses, a 36% increase in procedure volume, demonstrating rising demand for its innovative products. Reiterated full-year 2025 revenue guidance of $160.0 million to $175.0 ...

In addition, numerous surgeons will present their LAL experience at the RxSight booth in the convention exhibit hall (Booth #1911). A schedule of these presentations, which are not affiliated with the ...

Please provide your email address to receive an email when new articles are posted on . In 2013, Malvina B. Eydelman, MD, director of the FDA’s Division of Ophthalmic and Ear, Nose and Throat Devices, ...

ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following ...

Intraocular lens (IOL) design has continued to evolve since being introduced in 1949. We have seen an evolution not only in design, but also in material, optics, safety, and efficacy, among other ...

(MENAFN- GlobeNewsWire - Nasdaq) ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST)-- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality ...